- Home
- SND vs SKYE Comparison
SND vs SKYE Comparison
Compare SND & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SND
- SKYE
- Stock Information
- Founded
- SND 2011
- SKYE 2012
- Country
- SND United States
- SKYE United States
- Employees
- SND N/A
- SKYE N/A
- Industry
- SND Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- SND Industrials
- SKYE Health Care
- Exchange
- SND Nasdaq
- SKYE Nasdaq
- Market Cap
- SND 92.1M
- SKYE 101.3M
- IPO Year
- SND 2016
- SKYE N/A
- Fundamental
- Price
- SND $2.00
- SKYE $3.29
- Analyst Decision
- SND
- SKYE Buy
- Analyst Count
- SND 0
- SKYE 7
- Target Price
- SND N/A
- SKYE $15.50
- AVG Volume (30 Days)
- SND 103.7K
- SKYE 313.7K
- Earning Date
- SND 08-12-2025
- SKYE 08-07-2025
- Dividend Yield
- SND 5.03%
- SKYE N/A
- EPS Growth
- SND N/A
- SKYE N/A
- EPS
- SND 0.02
- SKYE N/A
- Revenue
- SND $305,848,000.00
- SKYE N/A
- Revenue This Year
- SND N/A
- SKYE N/A
- Revenue Next Year
- SND N/A
- SKYE N/A
- P/E Ratio
- SND $97.40
- SKYE N/A
- Revenue Growth
- SND 3.43
- SKYE N/A
- 52 Week Low
- SND $1.76
- SKYE $1.14
- 52 Week High
- SND $2.80
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- SND 55.72
- SKYE 44.67
- Support Level
- SND $1.94
- SKYE $3.23
- Resistance Level
- SND $2.04
- SKYE $3.75
- Average True Range (ATR)
- SND 0.08
- SKYE 0.30
- MACD
- SND 0.01
- SKYE -0.02
- Stochastic Oscillator
- SND 82.61
- SKYE 29.76
About SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.